Immuron achieves record quarterly Travelan® sales
2023年10月11日 - 7:00PM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company is pleased to
announce record quarterly sales (unaudited net sales) of its
over-the-counter gastrointestinal and digestive health immune
supplement Travelan®.
Australia
Immuron previously reported (August 9, 2023)
that short term stock outages of Travelan® in some wholesalers and
pharmacies in the June 2023 quarter was resolved following receipt
of GMP Clearance from the Therapeutic Goods Administration (TGA).
Immuron has since supplied product to wholesalers who in turn have
supplied retail pharmacies.
Sales of Travelan® increased to AUD $1,339,160
in Q1, FY24, compared to AUD $25,565 in Q1, FY23. Sales increased
by $940,991 (236%) on the pre-pandemic peak period (Q1, FY20). This
increase partially reflects 3 months (May, June, July) of
backorders accrued while awaiting GMP Clearance from the TGA.
Immuron anticipates continued demand for replenishment of
Travelan® as retail pharmacies sell to consumers. Australian Bureau
of Statistics: short term resident returns in July 2023 were 48%
higher than July 2022 and approaching pre-pandemic levels (89% of
July 2019)1. Cumulative short term resident returns in the 12
months to July 2023 were 77% of those in the pre-pandemic period 12
months to July 2019. 1
USA
Sales of Travelan® increased to AUD $211,080 in
Q1, FY24, compared to AUD $16,614 in Q1, FY23. Sales were lower by
$20,499 (-9%) on the pre-pandemic peak period (Q1, FY20).
International Trade Administration Total U.S. citizen
international visitor departures from the United States in June
2023 increased 20.2% compared to June 2022 and were 99.4% of total
departures in June 2019. 2
Immuron’s target departure markets 3, June 2023 quarter
departures were only 3% lower than the pre-pandemic period June
2019. 2
Immuron previously reported (July 5, 2023) that it had shipped
inventory to Amazon for launch in USA. The Amazon launch has been
progressing well with sales ahead of budget. We are now entering
the low travel season in USA. Immuron anticipates sales to grow
strongly closer to the peak spring / summer travel period.
-
https://www.abs.gov.au/statistics/industry/tourism-and-transport/overseas-arrivals-and-departures-australia/latest-release
-
https://www.trade.gov/sites/default/files/2023-09/US-Outbound-to-World-Regions.xlsx
- Caribbean, Asia, South America, Central America, Africa,
Mexico
This release has been authorised by the directors of Immuron
Limited.
COMPANY CONTACT:
Steven LydeamoreChief Executive OfficerPh: +61
(0)3 9824 5254info@immuron.com
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases.
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
過去 株価チャート
から 5 2024 まで 6 2024
Immuron (NASDAQ:IMRN)
過去 株価チャート
から 6 2023 まで 6 2024